Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C

Details for Australian Patent Application No. 2004258750 (hide)

Owner Idenix (Cayman) Limited L'Universite Montpellier II Centre National De La Recherche Scientifique -CNRS

Inventors Storer, Richard; Leroy, Frederic; Dukhan, David; Gosselin, Gilles

Agent Blake Dawson Waldron

Pub. Number AU-A-2004258750

PCT Pub. Number WO2005/009418

Priority 60/490,216 25.07.03 US

Filing date 26 July 2004

Wipo publication date 3 February 2005

International Classifications

C07H 19/044 (2006.01) Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical

A61K 31/706 (2006.01)

A61P 31/14 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

C07H 19/052 (2006.01) Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical

C07H 19/056 (2006.01) Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical

Event Publications

16 February 2006 PCT application entered the National Phase

  PCT publication WO2005/009418 Priority application(s): WO2005/009418

15 May 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004258751-The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity

2004258747-Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds